EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy

Haokang Feng, Jiale Feng, Xu Han iD, Ying Ying, Wenhui Lou, Liang Liu, Lei Zhang

Cancers · 10.01.2024 · 16 (2) · 289

DOI: 10.3390/cancers16020289 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 10.01.2024. Verfasst von Haokang Feng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shanghai, Open Fund of Key Laboratory of Hepatoaplenic Surgery, Ministry of Education, Harbin, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The dysregulation of sialic acid is closely associated with oncogenesis and tumor progression. Most tumor cells exhibit sialic acid upregulation. Sialic acid-binding immunoglobulin-like lectins (Siglecs) are receptors that recognize sialic acid and are expressed in various immune cells. The activity of Siglecs in the tumor microenvironment promotes immune escape, mirroring the mechanisms of the well-characterized PD-1/PD-L1 pathway in cancer. Cancer cells utilize sialic acid-linked glycans to evade immune surveillance. As Siglecs exhibit similar mechanisms as the established immune checkpoint inhibitors (ICIs), they are potential therapeutic targets for different forms of cancer, especially ICI-resistant malignancies. Additionally, the upregulation of sialic acid serves as a potential tumor biomarker. This review examines the feasibility of using sialic acid and Siglecs for early malignant tumor detection and discusses the potential of targeting Siglec–sialic acid interaction as a novel cancer therapeutic strategy.

Schlagwörter

Stichwörter der Autor:innen

Siglecsimmune cellsimmune checkpoint inhibitorsimmune evasionsialylation

Autor:innen und Institutionen

  • Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
  • Cancer Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
  • Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
  • The Shanghai Geriatrics Medical Center, Zhongshan Hospital MinHang MeiLong Branch, Fudan University, Shanghai 200032, China.

ORCID-Profile: Xu Han

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Shanghai
  • Open Fund of Key Laboratory of Hepatoaplenic Surgery, Ministry of Education, Harbin, China
  • Open Fund of the Key Laboratory of Hepatosplenic Surgery, Ministry of Education, Harbin, China
  • CSCO Cancer Research FundProiect

Zitieren

APA

Feng, H., Feng, J., Han, X., Ying, Y., Lou, W., Liu, L., & Zhang, L. (2024). The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy. Cancers, 16(2), 289. https://doi.org/10.3390/cancers16020289

Vancouver

Feng H, Feng J, Han X, Ying Y, Lou W, Liu L, et al. The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy. Cancers. 2024;16(2):289. doi:10.3390/cancers16020289

BibTeX
@article{Feng2024,
  author = {Feng, Haokang and Feng, Jiale and Han, Xu and Ying, Ying and Lou, Wenhui and Liu, Liang and Zhang, Lei},
  title = {The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {2},
  pages = {289},
  doi = {10.3390/cancers16020289}
}
Kostenlos starten →